Long-term follow-up of people treated with genetically modified T cells
Follows people with blood cancers for up to 15 years after CAR T cell therapy.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Key facts
- Where
- Glasgow, London, Manchester, and Newcastle upon Tyne, United KingdomSee the 5 sites
- Phase
- Phase 2
Where in United Kingdom
- Queen Elizabeth University HospitalGlasgow, United KingdomNo longer taking part
- University College London Hospitals NHS Foundation TrustLondon, United KingdomNo longer taking part
- Manchester Royal Infirmary HospitalManchester, United KingdomNo longer taking part
- Royal Manchester Children's HospitalManchester, United KingdomNo longer taking part
- Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation TrustNewcastle upon Tyne, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Autolus Limited
- Trial code
- NCT03628612
- Record updated
- 22 September 2026
- Original description
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.Read full original descriptionShow less
Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral Vectors
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
Inclusion: Patients must have received an AUTO CAR T cell therapy on a clinical treatment study; Patients must have provided informed consent for long-term follow-up study prior to participation; Patients must be able to comply with the study requirements.
Exclusion: There are no specific exclusion criteria for this study.